FRACTYL HEALTH, INC. (GUTS) Guidance & Earnings Results
On 2026-08-10 FRACTYL HEALTH, INC. reaffirmed guidance: "Cash runway into early 2027, beyond anticipated pivotal data readout and FDA De Novo…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GUTSFRACTYL HEALTH, INC.Follow GUTS — free
—
Price chart with a free account
- Market cap
- 14.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 10 Aug 26 | Reaffirmed | Cash runway into early 2027, beyond anticipated pivotal data readout and FDA De Novo submission |
| 12 May 26 | Reaffirmed | Cash runway into early 2027; Q2 2026: 1-year REVEAL-1 Cohort data; Q3 2026: 1-year REMAIN-1 Midpoint Cohort randomized data; Early Q4 2026: Topline 6-month randomized data from REMAIN-1 Pivotal Cohort; Late Q4 2026: Potential FDA De Novo marketing application submission |
| 24 Mar 26 | Reaffirmed | Cash runway into early 2027 |
FRACTYL HEALTH, INC. — questions
- What guidance did FRACTYL HEALTH, INC. give?
- On 2026-08-10: "Cash runway into early 2027, beyond anticipated pivotal data readout and FDA De Novo submission"
- When does FRACTYL HEALTH, INC. report earnings?
- FRACTYL HEALTH, INC.'s next earnings report is expected on 2026-11-11.
Every figure on this page comes from FRACTYL HEALTH, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.